The BCL-2 arbiters of apoptosis and their growing role as cancer targets

Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics

Kerr, J. F. R., Wyllie, A. H., & Currie, A. R. (1972) · British Journal of Cancer · doi:10.1038/bjc.1972.33 · Cited by 15,673 · see citing works

The landscape of somatic copy-number alteration across human cancers

Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017 · see citing works

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407 · see citing works

Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells

Vaux, D., Cory, S., & Adams, J. (1988) · Nature · doi:10.1038/335440a0 · Cited by 3,355 · see citing works

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219 · see citing works

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058 · see citing works

Induction of apoptosis in fibroblasts by c-myc protein

Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M. W., Waters, C. M., Penn, L. Z., & Hancock, D. C. (1992) · Cell · doi:10.1016/0092-8674(92)90123-t · Cited by 2,941 · see citing works

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992 · see citing works

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,901 · see citing works

Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function

Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., & Huang, D. C. S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.030 · Cited by 1,816 · see citing works

BCL-2 family proteins: changing partners in the dance towards death

Kale, J., Osterlund, E. J., & Andrews, D. W. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.186 · Cited by 1,574 · see citing works

The Combined Functions of Proapoptotic Bcl-2 Family Members Bak and Bax Are Essential for Normal Development of Multiple Tissues

Lindsten, T., Ross, A. J., King, A., Zong, W.-X., Rathmell, J. C., Shiels, H. A., Ulrich, E., Waymire, K. G., Mahar, P., Frauwirth, K., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00136-2 · Cited by 1,489 · see citing works

Structure of Bcl-x _L -Bak Peptide Complex: Recognition Between Regulators of Apoptosis

Sattler, M., Liang, H., Nettesheim, D., Meadows, R. P., Harlan, J. E., Eberstadt, M., Yoon, H. S., Shuker, S. B., Chang, B. S., Minn, A. J., et al. (1997) · Science · doi:10.1126/science.275.5302.983 · Cited by 1,476 · see citing works

X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death

Muchmore, S. W., Sattler, M., Liang, H., Meadows, R. P., Harlan, J. E., Yoon, H. S., Nettesheim, D. G., Chang, B. S., Thompson, C. B., Wong, S., et al. (1996) · Nature · doi:10.1038/381335a0 · Cited by 1,467 · see citing works

p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa

Villunger, A., Michalak, E. M., Coultas, L., Müllauer, F., Böck, G., Ausserlechner, M. J., Adams, J. M., & Strasser, A. (2003) · Science · doi:10.1126/science.1090072 · Cited by 1,327 · see citing works

Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members

Certo, M. V., Moore, V. D. G., Nishino, M., Wei, G., Korsmeyer, S. J., Armstrong, S. A., & Letai, A. G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.027 · Cited by 1,290 · see citing works

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized

van Delft, M. F., Wei, A. H., Mason, K. D., Vandenberg, C. J., Chen, L., Czabotar, P. E., Willis, S. N., Scott, C. L., Day, C. L., Cory, S., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.027 · Cited by 1,237 · see citing works

Proapoptotic Bak is sequestered by Mcl-1 and Bcl-x L , but not Bcl-2, until displaced by BH3-only proteinsPreprint

Willis, S. N., Chen, L., Dewson, G., Wei, A. H., Naik, E., Fletcher, J. I., Adams, J. M., & Huang, D. C. S. (2005) · Genes & Development · doi:10.1101/gad.1304105 · Cited by 1,236 · see citing works

bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation

McDonnell, T. J., Deane, N., Platt, F. M., Nunez, G., Jaeger, U., McKearn, J. P., & Korsmeyer, S. J. (1989) · Cell · doi:10.1016/0092-8674(89)90174-8 · Cited by 1,213 · see citing works

bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes

Sentman, C. L., Shutter, J. R., Hockenbery, D. M., Kanagawa, O., & Korsmeyer, S. J. (1991) · Cell · doi:10.1016/0092-8674(91)90361-2 · Cited by 1,194 · see citing works

BH3 Domains of BH3-Only Proteins Differentially Regulate Bax-Mediated Mitochondrial Membrane Permeabilization Both Directly and Indirectly

Kuwana, T., Bouchier-Hayes, L., Chipuk, J. E., Bonzon, C., Sullivan, B. A., Green, D. R., & Newmeyer, D. D. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.02.003 · Cited by 1,185 · see citing works

Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak

Willis, S. N., Fletcher, J. I., Kaufmann, T., van Delft, M. F., Chen, L., Czabotar, P. E., Ierino, H., Lee, E. F., Fairlie, W. D., Bouillet, P., et al. (2007) · Science · doi:10.1126/science.1133289 · Cited by 1,125 · see citing works

Structure of Bax

Suzuki, M., Youle, R. J., & Tjandra, N. (2000) · Cell · doi:10.1016/s0092-8674(00)00167-7 · Cited by 1,104 · see citing works

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

Konopleva, M. Y., Pollyea, D. A., Potluri, J., Chyla, B., Hogdal, L. J., Busman, T. A., McKeegan, E. M., Salem, A. H., Zhu, M., Ricker, J. L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0313 · Cited by 1,067 · see citing works

bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship

Strasser, A., Harris, A. W., & Cory, S. (1991) · Cell · doi:10.1016/0092-8674(91)90362-3 · Cited by 1,054 · see citing works

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A. L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G. L., Gong, J.-N., Moujalled, D. M., et al. (2016) · Nature · doi:10.1038/nature19830 · Cited by 1,047 · see citing works

Programmed Anuclear Cell Death Delimits Platelet Life Span

Mason, K. D., Carpinelli, M. R., Fletcher, J. I., Collinge, J. E., Hilton, A. A., Ellis, S., Kelly, P. N., Ekert, P. G., Metcalf, D., Roberts, A. W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.037 · Cited by 1,031 · see citing works

Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2

Strasser, A., Harris, A. W., Bath, M. L., & Cory, S. (1990) · Nature · doi:10.1038/348331a0 · Cited by 905 · see citing works

From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors

Ashkenazi, A., Fairbrother, W. J., Leverson, J. D., & Souers, A. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.253 · Cited by 903 · see citing works

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

Wilson, W. H., O'Connor, O. A., Czuczman, M. S., LaCasce, A. S., Gerecitano, J. F., Leonard, J. P., Tulpule, A., Dunleavy, K., Xiong, H., Chiu, Y.-L., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70261-8 · Cited by 876 · cited 1× · see citing works

Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease.

Strasser, A., Whittingham, S., Vaux, D. L., Bath, M. L., Adams, J. M., Cory, S., & Harris, A. W. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.19.8661 · Cited by 861 · see citing works

VDAC2 Inhibits BAK Activation and Mitochondrial Apoptosis

Cheng, E. H.-Y., Sheiko, T. V., Fisher, J. K., Craigen, W. J., & Korsmeyer, S. J. (2003) · Science · doi:10.1126/science.1083995 · Cited by 852 · see citing works

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

Roberts, A. W., Seymour, J. F., Brown, J. R., Wierda, W. G., Kipps, T. J., Khaw, S. L., Carney, D. A., He, S., Huang, D. C. S., Xiong, H., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7898 · Cited by 833 · see citing works

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

Stilgenbauer, S., Eichhorst, B. F., Schetelig, J., Coutre, S. E., Seymour, J. F., Munir, T., Puvvada, S. D., Wendtner, C., Roberts, A. W., Jurczak, W. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30019-5 · Cited by 809 · see citing works

Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1

Opferman, J. T., Letai, A. G., Beard, C., Sorcinelli, M. D., Ong, C. C., & Korsmeyer, S. J. (2003) · Nature · doi:10.1038/nature02067 · Cited by 801 · see citing works

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Davids, M. S., Roberts, A. W., Seymour, J. F., Pagel, J. M., Kahl, B. S., Wierda, W. G., Puvvada, S. D., Kipps, T. J., Anderson, M. A., Salem, A. H., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.4320 · Cited by 746 · see citing works

BAX activation is initiated at a novel interaction site

Gavathiotis, E., Suzuki, M., Davis, M. L., Pitter, K., Bird, G. H., Katz, S. G., Tu, H.-C., Kim, H., Cheng, E. H.-Y., Tjandra, N., et al. (2008) · Nature · doi:10.1038/nature07396 · Cited by 700 · see citing works

MOMP, cell suicide as a BCL-2 family business

Kalkavan, H., & Green, D. R. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.179 · Cited by 667 · see citing works

Bcl-xL Retrotranslocates Bax from the Mitochondria into the Cytosol

Edlich, F., Banerjee, S., Suzuki, M., Cleland, M. M., Arnoult, D., Wang, C., Neutzner, A., Tjandra, N., & Youle, R. J. (2011) · Cell · doi:10.1016/j.cell.2011.02.034 · Cited by 630 · see citing works

BCL-2 family antagonists for cancer therapy

Lessène, G., Czabotar, P. E., & Colman, P. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2658 · Cited by 623 · see citing works

Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737

Moore, V. D. G., Brown, J. R., Certo, M. V., Love, T. M., Novina, C. D., & Letai, A. G. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28281 · Cited by 604 · see citing works

Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

Chonghaile, T. N., Sarosiek, K. A., Vo, T.-T. T., Ryan, J. A., Tammareddi, A., Moore, V. D. G., Deng, J., Anderson, K. C., Richardson, P. G. G., Tai, Y., et al. (2011) · Science · doi:10.1126/science.1206727 · Cited by 588 · see citing works

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia

Chan, S. M., Thomas, D., Corces, M. R., Xavy, S., Rastogi, S., Hong, W., Zhao, F., Medeiros, B. C., Tyvoll, D. A., & Majeti, R. (2015) · Nature Medicine · doi:10.1038/nm.3788 · Cited by 580 · see citing works

Bax Crystal Structures Reveal How BH3 Domains Activate Bax and Nucleate Its Oligomerization to Induce Apoptosis

Czabotar, P. E., Westphal, D., Dewson, G., Ma, S., Hockings, C., Fairlie, W. D., Lee, E. F., Yao, S., Robin, A. Y., Smith, B. J., et al. (2013) · Cell · doi:10.1016/j.cell.2012.12.031 · Cited by 573 · see citing works

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

Leverson, J. D., Phillips, D. C., Mitten, M. J., Boghaert, E. R., Diaz, D., Tahir, S. K., Belmont, L. D., Nimmer, P., Xiao, Y., Ma, X. M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4642 · Cited by 541 · see citing works

Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases

Strasser, A., Cory, S., & Adams, J. M. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.307 · Cited by 530 · see citing works

Bim is a suppressor of Myc-induced mouse B cell leukemia

Egle, A., Harris, A. W., Bouillet, P., & Cory, S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401471101 · Cited by 482 · see citing works

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

Leverson, J. D., Zhang, H., Chen, J., Tahir, S. K., Phillips, D. C., Xue, J., Nimmer, P., Jin, S., Smith, M., Xiao, Y., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2014.561 · Cited by 440 · see citing works

Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemiaPreprint

Glaser, S. P., Lee, E. F., Trounson, E., Bouillet, P., Wei, A. H., Fairlie, W. D., Izon, D. J., Zuber, J. A., Rappaport, A., Herold, M. J., et al. (2012) · Genes & Development · doi:10.1101/gad.182980.111 · Cited by 427 · see citing works

Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals

Limpens, J., Stad, R. K., Vos, C., et al. (1995) · Blood · doi:10.1182/blood.v85.9.2528.bloodjournal8592528 · Cited by 420 · see citing works

Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration

Perciavalle, R. M., Stewart, D. P., Koss, B. S., Lynch, J., Milasta, S., Bathina, M., Temirov, J. P., Harwig, M. C., Pelletier, S. W., Schuetz, J. D., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2488 · Cited by 407 · see citing works

An informatics approach identifying markers of chemosensitivity in human cancer cell lines.

Amundson, S. A., Myers, T. G., Scudiero, D. A., Kitada, S., Reed, J. C., & Fornace, A. J. (2000) · PubMed · Cited by 399 · see citing works

Structure-guided design of a selective BCL-XL inhibitor

Lessène, G., Czabotar, P. E., Sleebs, B. E., Zobel, K., Lowes, K. N., Adams, J. M., Baell, J. B., Colman, P. M., Deshayes, K., Fairbrother, W. J., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1246 · Cited by 381 · see citing works

Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis

Annis, M. G., Soucie, E. L., Dlugosz, P. J., Cruz-Aguado, J. A., Penn, L. Z., Leber, B. F., & Andrews, D. W. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600675 · Cited by 377 · see citing works

Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1

Yecies, D. W., Carlson, N. E., Deng, J., & Letai, A. G. (2010) · Blood · doi:10.1182/blood-2009-07-233304 · Cited by 362 · see citing works

The Structure of a Bcl-xL/Bim Fragment Complex

Liu, X., Dai, S., Zhu, Y., Marrack, P., & Kappler, J. W. (2003) · Immunity · doi:10.1016/s1074-7613(03)00234-6 · Cited by 358 · see citing works

Anti-apoptotic BCL-2 family members in development

Opferman, J. T., & Kothari, A. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.170 · Cited by 349 · see citing works

To Trigger Apoptosis, Bak Exposes Its BH3 Domain and Homodimerizes via BH3:Groove Interactions

Dewson, G., Kratina, T., Sim, H. W., Puthalakath, H., Adams, J. M., Colman, P. M., & Kluck, R. M. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.005 · Cited by 348 · see citing works

Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML

Vo, T.-T. T., Ryan, J. A., Carrasco, R. D., Neuberg, D. S., Rossi, D. J., Stone, R. M., DeAngelo, D. J., Frattini, M. G., & Letai, A. G. (2012) · Cell · doi:10.1016/j.cell.2012.08.038 · Cited by 348 · see citing works

Apoptosis regulator Bcl-w is essential for spermatogenesis but appears otherwise redundant

Print, C. G., Loveland, K. L., Gibson, L., Meehan, T., Stylianou, A., Wreford, N. G., de Kretser, D., Metcalf, D., Köntgen, F., Adams, J. M., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.21.12424 · Cited by 335 · see citing works

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study

Seymour, J. F., Ma, S., Brander, D. M., Choi, M. Y., Barrientos, J. C., Davids, M. S., Anderson, M. A., Beaven, A., Rosen, S. T., Tam, C. S. L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30012-8 · Cited by 333 · see citing works

Why do BCL-2 inhibitors work and where should we use them in the clinic?

Montero, J., & Letai, A. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.183 · Cited by 325 · see citing works

Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane

O'Neill, K. L., Huang, K., Zhang, J., Chen, Y., & Luo, X. (2016) · Genes & Development · doi:10.1101/gad.276725.115 · Cited by 323 · see citing works

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism

Anderson, M. A., Deng, J., Seymour, J. F., Tam, C. S. L., Kim, S. Y., Fein, J. A., Yu, L., Brown, J. R., Westerman, D., Si, E. G., et al. (2016) · Blood · doi:10.1182/blood-2016-01-688796 · Cited by 317 · see citing works

BH3-Triggered Structural Reorganization Drives the Activation of Proapoptotic BAX

Gavathiotis, E., Reyna, D. E., Davis, M. L., Bird, G. H., & Walensky, L. D. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.10.019 · Cited by 310 · see citing works

Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM

Tagawa, H., Karnan, S., Suzuki, R., Matsuo, K., Zhang, X., Ota, A., Morishima, Y., Nakamura, S., & Seto, M. (2004) · Oncogene · doi:10.1038/sj.onc.1208300 · Cited by 307 · see citing works

Bax assembly into rings and arcs in apoptotic mitochondria is linked to membrane pores

Salvador‐Gallego, R., Mund, M., Cosentino, K., Schneider, J., Unsay, J., Schraermeyer, U., Engelhardt, J., Ries, J., & García‐Sáez, A. J. (2016) · The EMBO Journal · doi:10.15252/embj.201593384 · Cited by 296 · see citing works

Bax assembles into large ring‐like structures remodeling the mitochondrial outer membrane in apoptosis

Große, L., Wurm, C. A., Brüser, C., Neumann, D., Jans, D. C., & Jakobs, S. (2016) · The EMBO Journal · doi:10.15252/embj.201592789 · Cited by 281 · see citing works

Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family

Lee, E. F., Czabotar, P. E., Smith, B. J., Deshayes, K., Zobel, K., Colman, P. M., & Fairlie, W. D. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402178 · Cited by 280 · see citing works

Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer

Vaillant, F., Mérino, D., Lee, L., Breslin, K. A., Pal, B., Ritchie, M. E., Smyth, G. K., Christie, M., Phillipson, L. J., Burns, C. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.06.002 · Cited by 275 · see citing works

Loss of MCL-1 leads to impaired autophagy and rapid development of heart failurePreprint

Thomas, R. L., Roberts, D. J., Kubli, D. A., Lee, Y., Quinsay, M. N., Owens, J. B., Fischer, K. M., Sussman, M. A., Miyamoto, S., & Gustafsson, Å. B. (2013) · Genes & Development · doi:10.1101/gad.215871.113 · Cited by 268 · see citing works

Structural Model of Active Bax at the Membrane

Bleicken, S., Jeschke, G., Stegmueller, C., Salvador-Gallego, R., García-Sáez, A. J., & Bordignon, E. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.09.022 · Cited by 227 · see citing works

Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics

Sarosiek, K. A., Fraser, C. S., Muthalagu, N., Bhola, P. D., Chang, W., McBrayer, S. K., Cantlon, A., Fisch, S., Golomb‐Mello, G., Ryan, J. A., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.11.011 · Cited by 226 · see citing works

VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia

Egle, A., Harris, A. W., Bath, M. L., O’Reilly, L. A., & Cory, S. (2003) · Blood · doi:10.1182/blood-2003-07-2469 · Cited by 222 · see citing works

Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia

Cervantes-Gomez, F., Lamothe, B., Woyach, J. A., Wierda, W. G., Keating, M. J., Balakrishnan, K., & Gandhi, V. V. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2809 · Cited by 222 · see citing works

Bak Activation for Apoptosis Involves Oligomerization of Dimers via Their α6 Helices

Dewson, G., Kratina, T., Czabotar, P. E., Day, C. L., Adams, J. M., & Kluck, R. M. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.11.008 · Cited by 220 · see citing works

BID-induced structural changes in BAK promote apoptosis

Moldoveanu, T., Grace, C. R., Llambi, F., Nourse, A., Fitzgerald, P., Gehring, K., Kriwacki, R. W., & Green, D. R. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2563 · Cited by 201 · see citing works

ABT-199, a new Bcl-2–specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia

Vandenberg, C. J., & Cory, S. (2013) · Blood · doi:10.1182/blood-2013-01-475855 · Cited by 194 · see citing works

Mcl-1 Is a Key Regulator of Apoptosis during CNS Development and after DNA Damage

Arbour, N., Vanderluit, J. L., Grand, J. N. L., Jahani‐Asl, A., Ruzhynsky, V., Cheung, E. C., Kelly, M., MacKenzie, A., Park, D. S., Opferman, J. T., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.4940-07.2008 · Cited by 194 · see citing works

BH3-only proteins in apoptosis at a glance

Happo, L., Strasser, A., & Cory, S. (2012) · Journal of Cell Science · doi:10.1242/jcs.090514 · Cited by 193 · see citing works

Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells

Mérino, D., Khaw, S. L., Glaser, S. P., Anderson, D. J., Belmont, L. D., Wong, C., Yue, P., Robati, M., Phipson, B., Fairlie, W. D., et al. (2012) · Blood · doi:10.1182/blood-2011-12-400929 · Cited by 191 · see citing works

Bax dimerizes via a symmetric BH3:groove interface during apoptosis

Dewson, G., Ma, S., Frederick, P., Hockings, C., Tan, I., Kratina, T., & Kluck, R. M. (2012) · Cell Death & Differentiation · doi:10.1038/cdd.2011.138 · Cited by 189 · see citing works

BCL2 and miR-15/16: from gene discovery to treatment

Pekarsky, Y., Balatti, V., & Croce, C. M. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.159 · Cited by 189 · see citing works

Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer

Mérino, D., Whittle, J. R., Vaillant, F., Serrano, A., Gong, J.-N., Giner, G., Maragno, A. L., Chanrion, M., Schneider, E., Pal, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aam7049 · Cited by 186 · see citing works

Molecular Details of Bax Activation, Oligomerization, and Membrane Insertion

Bleicken, S., Classen, M., Padmavathi, P. V. L., Ishikawa, T., Zeth, K., Steinhoff, H., & Bordignon, E. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.081539 · Cited by 176 · see citing works

Differential retrotranslocation of mitochondrial Bax and Bak

Todt, F., Cakir, Z., Reichenbach, F., Emschermann, F., Lauterwasser, J., Kaiser, A., Ichim, G., Tait, S. W., Frank, S., Langer, H. F., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201488806 · Cited by 172 · see citing works

Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells

Carter, B. Z., Mak, P. Y., Mu, H. H., Zhou, H., Mak, D. H. F., Schober, W. D., Leverson, J. D., Zhang, B., Bhatia, R., Huang, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1180 · Cited by 170 · see citing works

Direct and selective small-molecule activation of proapoptotic BAX

Gavathiotis, E., Reyna, D. E., Bellairs, J. A., Leshchiner, E. S., & Walensky, L. D. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.995 · Cited by 169 · see citing works

The Bcl-2 family: structures, interactions and targets for drug discovery

Kvansakul, M., & Hinds, M. G. (2014) · APOPTOSIS · doi:10.1007/s10495-014-1051-7 · Cited by 168 · see citing works

Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment

Correia, C., Lee, S. H., Meng, X. W., Vincelette, N. D., Knorr, K. L. B., Ding, H., Nowakowski, G. S., Dai, H., & Kaufmann, S. H. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.03.012 · Cited by 167 · see citing works

Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53Preprint

Kelly, G. L., Grabow, S., Glaser, S. P., Fitzsimmons, L., Aubrey, B. J., Okamoto, T., Valente, L. J., Robati, M., Tai, L., Fairlie, W. D., et al. (2014) · Genes & Development · doi:10.1101/gad.232009.113 · Cited by 166 · see citing works

Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines

Zhang, H., Guttikonda, S. R., Roberts, L., Uziel, T., Semizarov, D., Elmore, S. W., Leverson, J. D., & Lam, L. T. (2010) · Oncogene · doi:10.1038/onc.2010.559 · Cited by 164 · see citing works

Bak Core and Latch Domains Separate during Activation, and Freed Core Domains Form Symmetric Homodimers

Brouwer, J. M., Westphal, D., Dewson, G., Robin, A. Y., Uren, R. T., Bartolo, R., Thompson, G. V., Colman, P. M., Kluck, R. M., & Czabotar, P. E. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.07.016 · Cited by 161 · see citing works

Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1

Teh, T.-C., Nguyen, N.-Y., Moujalled, D. M., Segal, D., Pomilio, G., Rijal, S., Jabbour, A. M., Cummins, K. D., Lackovic, K., Blombery, P. A., et al. (2017) · Leukemia · doi:10.1038/leu.2017.243 · Cited by 160 · see citing works

Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes #

Vick, B., Weber, A., Urbanik, T., Maass, T., Teufel, A., Krammer, P. H., Opferman, J. T., Schuchmann, M., Galle, P. R., & Schulze‐Bergkamen, H. (2008) · Hepatology · doi:10.1002/hep.22664 · Cited by 157 · see citing works

Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies

Roberts, A. W., & Huang, D. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.553 · Cited by 153 · see citing works

Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1

Gong, J.-N., Khong, T. T., Segal, D., Yao, Y., Riffkin, C. D., Garnier, J.-M., Khaw, S. L., Lessène, G., Spencer, A. G., Herold, M. J., et al. (2016) · Blood · doi:10.1182/blood-2016-03-704908 · Cited by 150 · see citing works

Targeting BCL-2-like Proteins to Kill Cancer Cells

Cory, S., Roberts, A. W., Colman, P. M., & Adams, J. M. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.07.001 · Cited by 147 · see citing works

VDAC2 is required for truncated BID‐induced mitochondrial apoptosis by recruiting BAK to the mitochondria

Roy, S. S., Ehrlich, A. M., Craigen, W. J., & Hajnóczky, G. (2009) · EMBO Reports · doi:10.1038/embor.2009.219 · Cited by 146 · see citing works

Selection against PUMA Gene Expression in Myc-Driven B-Cell Lymphomagenesis

Garrison, S. P., Jeffers, J. R., Yang, C., Nilsson, J. A., Hall, M. A., Rehg, J. E., Yue, W., Yu, J., Zhang, L., Onciu, M. M., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00907-07 · Cited by 145 · see citing works

Bax targets mitochondria by distinct mechanisms before or during apoptotic cell death: a requirement for VDAC2 or Bak for efficient Bax apoptotic function

Ma, S. B., Nguyen, T. N., Tan, I., Ninnis, R., Iyer, S., Stroud, D. A., Menard, M., Kluck, R. M., Ryan, M. T., & Dewson, G. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2014.119 · Cited by 138 · see citing works

In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas

Mason, K. D., Vandenberg, C. J., Scott, C. L., Wei, A. H., Cory, S., Huang, D. C. S., & Roberts, A. W. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809957105 · Cited by 136 · see citing works

A three-helix homo-oligomerization domain containing BH3 and BH1 is responsible for the apoptotic activity of BaxPreprint

George, N. M., Evans, J. J. D., & Luo, X. (2007) · Genes & Development · doi:10.1101/gad.1553607 · Cited by 132 · see citing works

Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax

Matulis, S. M., Gupta, V. A., Nooka, A. K., Hollen, H. V., Kaufman, J. L., Lonial, S., & Boise, L. (2015) · Leukemia · doi:10.1038/leu.2015.350 · Cited by 132 · see citing works

MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor

Xiao, Y., Nimmer, P. M., Sheppard, G. S., Bruncko, M., Hessler, P., Lu, X. L., Roberts-Rapp, L. A., Pappano, W. N., Elmore, S. W., Souers, A. J., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0928 · Cited by 122 · see citing works

Apoptotic pore formation is associated with in-plane insertion of Bak or Bax central helices into the mitochondrial outer membrane

Westphal, D., Dewson, G., Menard, M. J., Frederick, P., Iyer, S., Bartolo, R. C., Gibson, L., Czabotar, P. E., Smith, B. J., Adams, J. M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415142111 · Cited by 121 · see citing works

Viewing BCL2 and cell death control from an evolutionary perspective

Strasser, A., & Vaux, D. L. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.145 · Cited by 114 · see citing works

Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma

Richter, J. Á., Robles, E. F., Fresquet, V. J., Beltrán, E., Rullan, A., Agirre, X., Calasanz, M. J., Panizo, C., Richter, J. Á., Hernández‐Rivas, J. M., et al. (2010) · Blood · doi:10.1182/blood-2010-02-268003 · Cited by 113 · see citing works

Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL 2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD 20+ lymphoid malignancies

Roberts, A. W., Advani, R. H., Kahl, B. S., Persky, D. O., Sweetenham, J. W., Carney, D. A., Yang, J., Busman, T. A., Enschede, S. H., Humerickhouse, R., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13487 · Cited by 101 · see citing works

Disordered clusters of Bak dimers rupture mitochondria during apoptosis

Uren, R. T., O’Hely, M., Iyer, S., Bartolo, R. C., Shi, M. X., Brouwer, J. M., Alsop, A. E., Dewson, G., & Kluck, R. M. (2017) · eLife · doi:10.7554/elife.19944 · Cited by 97 · see citing works

Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia

Koss, B. S., Morrison, J. B., Perciavalle, R. M., Singh, H., Rehg, J. E., Williams, R. T., & Opferman, J. T. (2013) · Blood · doi:10.1182/blood-2012-06-440230 · Cited by 93 · see citing works

BH3‐in‐groove dimerization initiates and helix 9 dimerization expands Bax pore assembly in membranes

Zhang, Z., Subramaniam, S., Kale, J., Liao, C., Huang, B., Brahmbhatt, H., Condon, S. G., Lapolla, S. M., Hays, F. A., Ding, J., et al. (2016) · The EMBO Journal · doi:10.15252/embj.201591552 · Cited by 93 · see citing works

Activation of the Proapoptotic Bcl-2 Protein Bax by a Small Molecule Induces Tumor Cell Apoptosis

Zhao, G., Zhu, Y., Eno, C. O., Liu, Y., DeLeeuw, L. W., Burlison, J. A., Chaires, J. B., Trent, J. O., & Li, C. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00996-13 · Cited by 83 · see citing works

Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis

Brien, G., Trescol-Biemont, M.-C., & Bonnefoy, N. (2007) · Oncogene · doi:10.1038/sj.onc.1210363 · Cited by 80 · see citing works

Pore formation by dimeric Bak and Bax: an unusual pore?

Uren, R. T., Iyer, S., & Kluck, R. M. (2017) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2016.0218 · Cited by 79 · see citing works

Crystal structure of Bax bound to the BH3 peptide of Bim identifies important contacts for interaction

Robin, A. Y., Kumar, K. K., Westphal, D., Wardak, A. Z., Thompson, G. V., Dewson, G., Colman, P. M., & Czabotar, P. E. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.141 · Cited by 73 · see citing works

Organization of the Mitochondrial Apoptotic BAK Pore

Aluvila, S., Mandal, T., Hustedt, E., Fajer, P., Choe, J. Y., & Oh, K. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.526806 · Cited by 71 · see citing works

Assembly of the Bak Apoptotic Pore

Ma, S., Hockings, C., Anwari, K., Kratina, T., Fennell, S., Lazarou, M., Ryan, M. T., Kluck, R. M., & Dewson, G. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.490094 · Cited by 71 · see citing works

Characterisation of mice lacking all functional isoforms of the pro-survival BCL-2 family member A1 reveals minor defects in the haematopoietic compartment

Schenk, R. L., Tuzlak, S., Carrington, E. M., Zhan, Y., Heinzel, S., Teh, C. E., Gray, D. H. D., Tai, L., Lew, A. M., Villunger, A., et al. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2016.156 · Cited by 68 · see citing works

Progenitor tumours from Emu‐bcl‐2‐myc transgenic mice have lymphomyeloid differentiation potential and reveal developmental differences in cell survival.

Strasser, A., Elefanty, A. G., Harris, A. W., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00756.x · Cited by 65 · see citing works

Bak apoptotic pores involve a flexible C-terminal region and juxtaposition of the C-terminal transmembrane domains

Iyer, S., Bell, F., Westphal, D., Anwari, K., Gulbis, J. M., Smith, B. J., Dewson, G., & Kluck, R. M. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.15 · Cited by 64 · see citing works

Identification of an activation site in Bak and mitochondrial Bax triggered by antibodies

Iyer, S., Anwari, K., Alsop, A. E., Yuen, W. S., Huang, D. C. S., Carroll, J., Smith, N. A., Smith, B. J., Dewson, G., & Kluck, R. M. (2016) · Nature Communications · doi:10.1038/ncomms11734 · Cited by 58 · see citing works

Dissociation of Bak α1 helix from the core and latch domains is required for apoptosis

Alsop, A. E., Fennell, S. C., Bartolo, R. C., Tan, I. K. L., Dewson, G., & Kluck, R. M. (2015) · Nature Communications · doi:10.1038/ncomms7841 · Cited by 57 · see citing works

Genomic analysis and selective small molecule inhibition identifies BCL-XL as a critical survival factor in a subset of colorectal cancer

Zhang, H., Xue, J., Hessler, P., Tahir, S. K., Chen, J., Jin, S. S., Souers, A. J., Leverson, J. D., & Lam, L. T. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0397-y · Cited by 54 · see citing works

BCL-W has a fundamental role in B cell survival and lymphomagenesis

Adams, C. M., Kim, A. S., Mitra, R., Choi, J. K., Gong, J. Z., & Eischen, C. M. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89486 · Cited by 51 · see citing works

Pro-apoptotic Bax molecules densely populate the edges of membrane pores

Kuwana, T., Olson, N. H., Kiosses, W. B., Peters, B., & Newmeyer, D. D. (2016) · Scientific Reports · doi:10.1038/srep27299 · Cited by 50 · see citing works

Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients ≥ 65 years ineligible for standard induction therapy.

Pollyea, D. A., Dinardo, C. D., Thirman, M. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.7009 · Cited by 50 · see citing works

Haploinsufficiency of Bcl-x leads to male-specific defects in fetal germ cells: differential regulation of germ cell apoptosis between the sexes

Kasai, S., Chuma, S., Motoyama, N., & Nakatsuji, N. (2003) · Developmental Biology · doi:10.1016/s0012-1606(03)00400-7 · Cited by 46 · see citing works

Allosteric sensitization of proapoptotic BAX

Pritz, J. R., Wachter, F., Lee, S., Luccarelli, J., Wales, T. E., Cohen, D. T., Coote, P. W., Heffron, G. J., Engen, J. R., Massefski, W. W., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2433 · Cited by 45 · see citing works

MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice

Grabow, S., Delbridge, A. R. D., Valente, L. J., & Strasser, A. (2014) · Blood · doi:10.1182/blood-2014-09-601567 · Cited by 44 · see citing works

Abstract DDT01-02: AZD5991: A potent and selective macrocyclic inhibitor of Mcl-1 for treatment of hematologic cancers

Hird, A. W., Secrist, J. P., Adam, A., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-ddt01-02 · Cited by 22 · see citing works

Abstract DDT01-01: The discovery and preclinical characterization of AMG 176: A first-in-class Mcl-1 inhibitor in clinical development for multiple myeloma

Hughes, P. E. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-ddt01-01 · Cited by 5 · see citing works

Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS–) vs. Alternatively Activated Macrophages

Orecchioni, M., Ghosheh, Y., Pramod, A. B., & Ley, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01084 · Cited by 2,063 · see citing works

Cellular senescence: the good, the bad and the unknown

Huang, W., Hickson, L. J., Eirin, A., Kirkland, J. L., & Lerman, L. O. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00601-z · Cited by 1,150 · see citing works

PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers

Liu, R., Chen, Y., Liu, G., Li, C., Song, Y., Cao, Z., Li, W., Hu, J., Lu, C., & Liu, Y. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-02998-6 · Cited by 923 · see citing works

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

The Relationship between the Structural Characteristics of Lactobacilli-EPS and Its Ability to Induce Apoptosis in Colon Cancer Cells in Vitro

Tukenmez, U., Aktas, B., Aslim, B., & Yavuz, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-44753-8 · Cited by 167 · see citing works

p53 as a hub in cellular redox regulation and therapeutic target in cancer

Eriksson, S. E., Ceder, S., Bykov, V. J. N., & Wiman, K. G. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz005 · Cited by 123 · see citing works

BCL-XL expression is essential for human erythropoiesis and engraftment of hematopoietic stem cells

Afreen, S., Bohler, S., Müller, A., Demmerath, E.-M., Weiss, J. M., Jutzi, J. S., Schachtrup, K., Kunze, M., & Erlacher, M. (2020) · Cell Death & Disease · doi:10.1038/s41419-019-2203-z · Cited by 55 · see citing works

Potential of BCL2 as a target for chronic lymphocytic leukemia treatment

Moia, R., Diop, F., Favini, C., Kodipad, A. A., & Gaïdano, G. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1456332 · Cited by 19 · see citing works

Venetoclax (Venclexta™)

Finnes, H. D. (2017) · Oncology Times · doi:10.1097/01.cot.0000520170.87702.0f

[Research Advance of Venetoclax in Hematological Tumors--Review].

Chen, L., & Song, Y. (2020) · PubMed · doi:10.19746/j.cnki.issn.1009-2137.2020.04.058

Initiating venetoclax treatment: Clinical practice pearls

Prajapati, D. (2023) · Canadian Hematology Today · doi:10.58931/cht.2023.2235

Abstract 1134: The LSD1 inhibitor INCB059872 is a possible therapeutic option for venetoclax-resistant AML

Diamond, M. A., Chadderton, A. R., He, C., et al. (2021) · Cancer Research · doi:10.1158/1538-7445.am2021-1134 · Cited by 2 · see citing works